A state-of-art review on collagenase Clostridium Histolyticum and Peyronie’s disease: drug profile, clinical evidence and safety outcomes

References

• Chung E, Ralph D, Kadioglu A, et al. Evidence-based management guidelines on Peyronie’s disease. J Sex Med. 2016;13(6):905–923.
   PubMed Web of Science ®Google Scholar
• Nehra A, Alterowitz R, Culkin DJ, et al. Peyronie’s disease: AUA guideline. J Urol. 2015;194(3):745–753.
   PubMed Web of Science ®Google Scholar
• Chung E, De Young L, Brock GB. Rat as an animal model for Peyronie’s disease research: a review of current methods and the peer-reviewed literature. Int J Impot Res. 2011;23(6):235–241.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Cadavid NF, Rajfer J. Mechanisms of disease: new insights into the cellular and molecular pathology of Peyronie’s disease. Nat Clin Pract Urol. 2005;2:291–297.
   PubMedGoogle Scholar
• Weil L, Kocholaty W. Studies on the proteinase of Clostridium histolyticum. Biochem J. 1937;31:1255–1257.
   PubMedGoogle Scholar
• Starkweather KD, Lattuga S, Hurst LC, et al. Collagenase in the treatment of Dupuytren’s disease: an in vitro study. J Hand Surg. 1996;21(3):490–495.
   PubMedGoogle Scholar
• Nyberg LM Jr., Bias WB, Hochberg MC, et al. Identification of an inherited form of Peyronie’s disease with autosomal dominant inheritance and association with Dupuytren’s contracture and histocompatibility B7 cross-reacting antigens. J Urol. 1982;128(1):48–51.
   PubMed Web of Science ®Google Scholar
• Gelbard N, Walsh R, Kaufman J. Collagenase for Peyronie’s disease: experimental studies. Urol Res. 1982;10:135–140.
   PubMed Web of Science ®Google Scholar
• Gabrielson AT, Spitz JT, Hellstrom WJG. Collagenase clostridium histolyticum in the treatment of urologic disease: current and future impact. Sex Med Rev. 2018;6(1):143–156.
   PubMed Web of Science ®Google Scholar
• Van Wart HE, Steinbrink DR. Complementary substrate specificities of class I and class II collagenases from clostridium histolyticum. Biochemistry. 1985;24(23):6520–6526.
   PubMed Web of Science ®Google Scholar
• French M, Mookhtiar K, Van Wart H. Limited proteolysis of type 1 collagen at hyperreactive sites by class I and II clostridium histolyticum collagenases: complementary digestion patterns. Biochemistry. 1987;26:681–687.
   PubMed Web of Science ®Google Scholar
• Peak TC, Mitchell GC, Yafi FA, et al. Role of collagenase clostridium histolyticum in Peyronie’s disease. Biologics. 2015;9:107–116.
   PubMedGoogle Scholar
• Desai SS, Hentz V. Collagenase clostridium histolyticum for Dupuytren’s contracture. Exp Opin Biol Ther. 2010;10(9):1395–1404.
   PubMed Web of Science ®Google Scholar
• Auxilium, Pharmaceuticals. Pharmacokinetics of a single treatment cycle of AA4500 0.587mg in men with Peyronie’s disease. Bethesda, MD: National Library of Medicine; 2011.
   Google Scholar
• Auxilium, Pharmaceuticals. Xiaflex (Collagenase Clostridium Histolyticum) [prescribing information]. Chesterbrook, PA; 2014.
   Google Scholar
• Gelbard MK, Lindner A, Kaufman JJ. The use of collagenase in the treatment of Peyronie’s disease. Plast Reconstr Surg. 1986;78(4):548.
   Google Scholar
• Gelbard MK, James K, Riach P, et al. Collagenase versus placebo in the treatment of Peyronie’s disease: a double-blind study. J Urol. 1993;149(1):56–58.
   PubMed Web of Science ®Google Scholar
• Gelbard M, Lipshultz LI, Tursi J, et al. Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease. J Urol. 2012;187(6):2268–2274.
   PubMed Web of Science ®Google Scholar
• Gelbard M, Goldstein I, Hellstrom WJ, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo-controlled phase 3 studies. J Urol. 2013;190(1):199–207.
   PubMed Web of Science ®Google Scholar
• Hellstrom WJ, Feldman R, Rosen RC, et al. Bother and distress associated with Peyronie’s disease: validation of the Peyronie’s disease questionnaire. J Urol. 2013;190(2):627–634.
   PubMed Web of Science ®Google Scholar
• Goldstein I, Knoll LD, Lipshultz LI, et al. Changes in the effects of Peyronie’s disease after treatment with collagenase clostridium histolyticum: male patients and their female partners. Sex Med. 2017;5(2):e124–e130.
   PubMed Web of Science ®Google Scholar
• Levine LA, Cuzin B, Mark S, et al. Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie’s disease: a phase 3 open-label study. J Sex Med. 2015;12(1):248–258.
   PubMed Web of Science ®Google Scholar
• Ziegelmann MJ, Viers BR, McAlvany KL, et al. Restoration of penile function and patient satisfaction with intralesional Collagenase Clostridium Histolyticum injection for Peyronie’s Disease. J Urol. 2016;195(4 Pt 1):1051–1056.
   PubMedGoogle Scholar
• Anaissie J, Yafi FA, DeLay KJ, et al. Impact of number of cycles of collagenase Clostridium Histolyticum on outcomes in patients with Peyronie’s disease. Urology. 2017;100:125–130.
   PubMed Web of Science ®Google Scholar
• Cocci A, Cito G, Urzi D, et al. Sildenafil 25mg ODT + collagenase clostridium histolyticum vs collagenase histolyticum alone for the management of Peyronie’s disease: A matched-pair comparison analysis. J Sex Med. 2018;15(10):1472–1477.
   PubMed Web of Science ®Google Scholar
• Russo G, Milenkovic U, Hellstrom W, et al. Clinical efficacy of injection and mechanical therapy for Peyronie’s disease: A systematic review of the literature. Eur Urol. 2018;74(6):767–781.
   PubMed Web of Science ®Google Scholar
• Yafi FA, Diao L, DeLay KJ, et al. Multi-institutional prospective analysis of intralesional injection of collagenase clostridium histolyticum, tunical plication, and partial plaque excision and grafting for the management of Peyronie’s disease. Urology. 2018;120:138–142.
   PubMed Web of Science ®Google Scholar
• Cocci A, Russo GI, Briganti A, et al. Predictors of treatment success after collagenase clostridium histolyticum injection for Peyronie’s disease: development of a nomogram from a multicentre single-arm, non-placebo controlled clinical study. BJU Int. 2018;122(4):680–687.
   PubMed Web of Science ®Google Scholar
• Cocci A, Russo GI, Salonia A, et al. Predictive factors of patients’ and their partners’ sexual function improvement after collagenase clostridium histolyticum injection for Peyronie’s disease: results from a multi-center single-arm study. J Sex Med. 2018;15(5):716–721.
   PubMed Web of Science ®Google Scholar
• Russo GI, Cacciamani G, Cocci A, et al. Comparative effectiveness of intralesional therapy for Peyronie’s disease in controlled clinical studies: A systematic review and network meta-analysis. J Sex Med. 2019;16(2):289–299.
   PubMed Web of Science ®Google Scholar
• Abdel Raheem A, Capece M, Kalejaiye O, et al. Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie’s disease using a new modified shortened protocol. BJU Int. 2017;120(5):717–723.
   PubMed Web of Science ®Google Scholar
• Capece M, Cocci A, Russo G, et al. Collagenase clostridium histolyticum for the treatment of Peyronie’s disease: a prospective Italian multicentric study. Andrology. 2018;6(4):564–567.
   PubMed Web of Science ®Google Scholar
• Carson CC 3rd, Sadeghi-Nejad H, Tursi JP, et al. Analysis of the clinical safety of intralesional injection of collagenase Clostridium histolyticum (CCH) for adults with Peyronie’s disease (PD). BJU Int. 2015;116(5):815–822.
   PubMed Web of Science ®Google Scholar
• Hellstrom WJG, Tan RBW, Liu G. Safety profile of collagenase Clostridium Histolyticum stratified by degree of penile curvature in patients with Peyronie’s disease. Urology. 2017;106:e9–237.
   PubMed Web of Science ®Google Scholar
• Beilan JA, Wallen JJ, Baumgarten AS, et al. Intralesional injection of collagenase clostrididum histolyticum may increase the risk of late-onset penile fracture. Sex Med Rev. 2018;6(2):272–278.
   PubMed Web of Science ®Google Scholar
• Nguyen HMT, Anaissie J, DeLay KJ, et al. Safety and efficacy of collagenase clostridium histolyticum in the treatment of acute-phase Peyronie’s disease. J Sex Med. 2017;14(10):1220–1225.
   PubMed Web of Science ®Google Scholar
• Yafi FA, Anaissie J, Zurawin J, et al. Results of SMSNA survey regarding complications following intralesional injection therapy with collagenase Clostridium Histolyticum for Peyronie’s disease. J Sex Med. 2016;13:684–689.
   PubMed Web of Science ®Google Scholar
• Cordon BH, Hofer MD, Hutchinson RC. et al. Superior cost effectiveness of penile plication vs intralesional collagenase injection for treatment of Peyronie’s disease deformities. Urol Pract. 2017;4(2):118–125.
   Google Scholar
• Cocci A, Russo GI, Salamanca JIM, et al. The end of an era: withdrawal of Xiapex (Clostridium histolyticum collagenase) from the European market. Eur Urol. 2019;S0302-2838(19)30892–9. DOI:10.1016/j.eururo.2019.11.019
   PubMedGoogle Scholar
• [cited 2019 Dec]. Available from: https://healthunlocked.com/menshealth-penishealth/posts/142171333/endo-pharmacauticals-has-discontinued-xiaflex-injection-in-australia-and-asia
   Google Scholar
• Chung E, De Young L, Solomon M, et al. Peyronie’s disease and mechanotransduction: an in vitro analysis of the cellular changes to Peyronie’s disease in a cell-culture strain system. J Sex Med. 2013;10(5):1259–1267.
   PubMed Web of Science ®Google Scholar